Success During Initial Treatment Period

In addition to efficient administration, efficacy during the acute treatment phase is a critically important feature of a surfactant. Rapidly improved oxygenation, sustained efficacy, and fewer doses can all help wean infants to less invasive forms of ventilation.

Explore 3 features of CUROSURF® (poractant alfa) efficacy that can help you experience fast RDS success:

Rapid onset of action: delivers better short-term efficacy

CUROSURF improves oxygenation within 5 minutes and rapidly reduces FiO2 requirements over the initial treatment period.1,2 It has been suggested that these results may allow you to wean infants off the ventilator sooner.3 As you can see below, infants treated with CUROSURF experienced faster FiO2 reduction than those treated with Survanta® (beractant) over a 6-hour period.3

Physiological end points (eg, faster reduction in FiO2) have not been proven to impact key clinical outcomes such as mortality due to RDS.

Faster reduction in FiO23

Rapid reduction of FiO2 levels may help you wean infants off the ventilator sooner.3

Reduction of FiO2 over 3 days for CUROSURF and SURVANTA

Adapted from Ramanathan R, et al. Am J Perinatol. 2004. FiO2 = fraction of inspired oxygen.

  • CUROSURF is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

Rapid reduction of FiO2 levels may help you wean infants off the ventilator sooner.3

Sustained Results with Fewer Doses

CUROSURF demonstrates consistent FiO2 reductions sustained over time 4,5

Difference in FiO2 over time*4

In a clinical trial, oxygen requirements did not rebound above redosing threshold (FiO2 ≥0.30) after first dose of CUROSURF® during the first 48 hours.4 Sustained reduction of FiO2 levels may reduce the need for redosing.4

FiO2 over time for CUROSURF and SURVANTA

Adapted from Malloy CA, et al. Acta Paediatr. 2005. (N=58)
*Shading indicates FiO2 range in which redosing was required. FiO2 = fraction of inspired oxygen.

In a clinical trial, oxygen requirements did not rebound above redosing threshold (FiO2 ≥0.30) after first dose of CUROSURF® during the first 48 hours.4 Sustained reduction of FiO2 levels may reduce the need for redosing.4

Respiratory index over first 3 days of life5

In a clinical trial, infants required lower respiratory support for the first 72 hours of life vs Survanta® (beractant)5

Respiratory index over 3 days for CUROSURF and SURVANTA

Adapted from Fujii AM, et al. J Perinatol. 2010. MAP = mean airway pressure.
FiO2 = fraction of inspired oxygen.

  • Lower respiratory requirements in the CUROSURF group could be attributed to a greater number of infants extubated at 48 and 72 hours vs Survanta5
  • Physiological end points (eg, lower respiratory index) have not been proven to impact key clinical outcomes such as mortality due to RDS

In a clinical trial, infants required lower respiratory support for the first 72 hours of life vs Survanta® (beractant)5

Consistently high rates of single-dose success

Single-dose success in clinical studies3,6-9

Across studies, infants treated with the 200 mg/kg initial dose of CUROSURF® (poractant alfa) demonstrated higher rates of single-dose success vs those treated with Survanta® (beractant).1,3,4,6

CLINICAL STUDY N* GESTATIONAL AGE CUROSURF (200 mg/kg)
SINGLE-DOSE SUCCESS
Dizdar EA, et al. 20116 126 Median 28 wks 88%
Sandri F, et al. 2010 (treatment arm) 7 103 Mean 27.0 ± 1.0 wks 78%
Dani C, et al. 2004 8 27 <30 wks 74%
Ramanathan R, et al. 2004 3 293 Mean 28.7 ± 2.0 wks 73%
Verder H, et al. 1999 9 60 25-29 wks 88%

*Total number of infants randomized.
Single-dose success is defined as no need for repeat doses of CUROSURF® (poractant alfa).

  • Limited need to redose may decrease the risks associated with reintubation and MV
  • Clinical studies have not established that fewer doses result in superior safety or efficacy based on clinically relevant end points

 

Across studies, infants treated with the 200 mg/kg initial dose of CUROSURF® (poractant alfa) demonstrated higher rates of single-dose success vs those treated with Survanta® (beractant).1,3,4,6